首页> 外文期刊>International Journal of Pharmacological Research >Antidepressant effect of Ziprasidone in wistar albino rat by forced swimming test model
【24h】

Antidepressant effect of Ziprasidone in wistar albino rat by forced swimming test model

机译:强制游泳试验模型对齐帕西酮对Wistar白化病大鼠的抗抑郁作用

获取原文
           

摘要

Background: Major depressive disorder is a common psychiatric condition and response conventional antidepressant drugs are sometimes unpredictable. Atypical antipsychotics by virtue of their pharmacodynamic profile show potential antidepressant effect. Newer antidepressants as monotherapy or as augmenting agent for current therapy are need of the day. Ziprasidone is an atypical antidepressant drug possesses potential antidepressant activity by virtue of its 5HT1A agonistic activity and 5HT1D, 5HT2A and D2 receptors antagonistic activity. Method : Since its introduction in 1977 the forced swimming test model is still being used for evaluation of potential antidepressant molecule. 30 healthy male Wistar albino rat of 150-200 grams weight were divided in 3 groups with 10 rats in each. Group A was treated with 0.9% Normal Saline, Group B with Fluoxetine and Group C with Ziprasidone for 42 days. Forced Swimming test was done on day 0, 7, 14, 21, 28, 35 and 42 days. Result: After 42 days of treatment both fluoxetine and ziprasidone shows significant antidepressant activity. In comparison to Normal saline both the drugs shows significant antidepressant activity. There is significant deference in antidepressant activity between Fluoxetine and Ziprasidone. Antidepressant activity of Fluoxetine started to appear from day 7 with p vale of 0.000 and of Ziprasidone started to appear from 14 days with p value of 0.000. Conclusion: Ziprasidone as virtue of its diverse pharmacodynamic effect can be suitable candidate for clinical trials of MDD as monotherapy or as an augmenting agent of standard antidepressant therapy.
机译:背景:重度抑郁症是一种常见的精神疾病,常规抗抑郁药的反应有时无法预测。非典型抗精神病药凭借其药效学特征显示出潜在的抗抑郁作用。如今需要新型抗抑郁药作为单一疗法或作为当前疗法的增强剂。 Ziprasidone是一种非典型的抗抑郁药,凭借其5HT1A激动活性以及5HT1D,5HT2A和D2受体的拮抗活性,具有潜在的抗抑郁活性。方法:自1977年问世以来,强迫游泳试验模型仍用于评估潜在的抗抑郁分子。将30只体重150-200克的健康雄性Wistar白化病大鼠分为3组,每组10只。 A组用0.9%生理盐水治疗,B组用氟西汀治疗,C组用齐普西酮治疗42天。在第0、7、14、21、28、35和42天进行了强迫游泳测试。结果:治疗42天后,氟西汀和齐拉西酮均显示出显着的抗抑郁活性。与生理盐水相比,两种药物均显示出显着的抗抑郁活性。氟西汀和齐普拉西酮之间的抗抑郁活性存在显着差异。氟西汀的抗抑郁活性从第7天开始出现,p值为0.000,齐普西酮从14天开始出现,p值为0.000。结论:齐帕西酮具有多种药效作用,可以作为单一疗法或作为标准抗抑郁药的增强剂进行MDD临床试验的合适人选。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号